He Jian, Xu Dengyue, Wang Lu, Yu Xiaohong
Department of Cardiovascular Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Department of Cardiovascular Surgery, General Hospital of Northern Theater Command of China Medical University, Shenyang, China.
Front Pharmacol. 2023 Jan 4;13:1079251. doi: 10.3389/fphar.2022.1079251. eCollection 2022.
Cardiovascular disease has become the primary disease that threatens human health and is considered the leading cause of death. Cardiac remodeling, which is associated with cardiovascular disease, mainly manifests as cardiac hypertrophy, fibrosis, inflammation, and oxidative stress. Farrerol plays an important role in treating conditions such as inflammation, endothelial injury and tumors, and we speculated that Farrerol may also play an important role in mitigating cardiac hypertrophy and remodeling. We established a model of myocardial remodeling using Angiotensin II (Ang II) with concurrent intraperitoneal injection of Farrerol as an intervention. We used cardiac ultrasound, immunohistochemistry, Immunofluorescence, Wheat Germ Agglutinin, Dihydroethidium, Western Blot, qPCR and other methods to detect the role of Farrerol in cardiac remodeling. The results showed that Farrerol inhibited Ang II-induced cardiac hypertrophy; decreased the ratio of heart weight to tibia length in mice; reduced inflammation, fibrosis, and oxidative stress; and reduced the size of cardiomyocytes . Farrerol inhibited Ang II-induced cardiomyocyte hypertrophy, levels of oxidative stress, and the proliferation and migration of fibroblast . Our results revealed that Farrerol could inhibit Ang II-induced cardiac remodeling. Farrerol may therefore be a candidate drug for the treatment of myocardial remodeling.
心血管疾病已成为威胁人类健康的主要疾病，并被认为是主要的死亡原因。与心血管疾病相关的心脏重塑主要表现为心脏肥大、纤维化、炎症和氧化应激。法尔瑞林在治疗炎症、内皮损伤和肿瘤等病症中发挥重要作用，我们推测法尔瑞林在减轻心脏肥大和重塑方面可能也发挥重要作用。我们使用血管紧张素 II（Ang II）建立心肌重塑模型，并同时腹腔注射法尔瑞林作为干预措施。我们采用心脏超声、免疫组织化学、免疫荧光、小麦胚凝集素、二氢乙锭、蛋白质免疫印迹、定量聚合酶链反应等方法来检测法尔瑞林在心脏重塑中的作用。结果表明，法尔瑞林抑制 Ang II 诱导的心脏肥大；降低小鼠心脏重量与胫骨长度的比值；减轻炎症、纤维化和氧化应激；并减小心肌细胞大小。法尔瑞林抑制 Ang II 诱导的心肌细胞肥大、氧化应激水平以及成纤维细胞的增殖和迁移。我们的结果表明，法尔瑞林可以抑制 Ang II 诱导的心脏重塑。因此，法尔瑞林可能是治疗心肌重塑的候选药物。
